Vascular nitrosative stress in hypertension induced by fetal undernutrition in rats

Fetal undernutrition predisposes to hypertension development. Since nitric oxide (NO) is a key factor in blood pressure control, we aimed to investigate the role of NO alterations in hypertension induced by fetal undernutrition in rats. Male and female offspring from dams exposed to undernutrition during the second half of gestation (MUN) were studied at 21 days (normotensive) and 6 months of age (hypertension developed only in males). In aorta, we analyzed total and phosphorylated endothelial NO synthase (eNOS, p-eNOS), 3-nitrotyrosine (3-NT), and Nrf2 (Western blot). In plasma we assessed L-arginine, asymmetric and symmetric dimethylarginine (ADMA, SDMA; LC–MS/MS), nitrates (NOx, Griess reaction), carbonyl groups, and lipid peroxidation (spectrophotometry). In iliac arteries, we studied superoxide anion production (DHE staining, confocal microscopy) and vasodilatation to acetylcholine (isometric tension). Twenty-one-day-old MUN offspring did not show alterations in vascular e-NOS or 3NT expression, plasma L-Arg/ADMA ratio, or NOx. Compared to control group, 6-month-old MUN rats showed increased aortic expression of p-eNOS/eNOS and 3-NT, being Nrf2 expression lower, elevated plasma L-arginine/ADMA, NOx and carbonyl levels, increased iliac artery DHE staining and reduced acetylcholine-mediated relaxations. These alterations in MUN rats were sex-dependent, affecting males. However, females showed some signs of endothelial dysfunction. We conclude that increased NO production in the context of a pro-oxidative environment, leads to vascular nitrosative damage and dysfunction, which can participate in hypertension development in MUN males. Females show a better adaptation, but signs of endothelial dysfunction, which can explain hypertension in ageing. (AU)

Contenido en Lisina y Arginina en soluciones de aminoácidos comercializadas en España / Comparison of Lysine and Arginine content in amino acid parenteral formulas approved in Spain

Introducción: La terapia basada en péptidos con radionúclidos representa una estrategia terapéutica eficaz frente a tumores neuroendocrinos pero no está exenta de efectos adversos como la nefrotoxicidad. Para prevenir esta nefrotoxicidad se emplean soluciones de aminoácidos de Lisina y Arginina. El objetivo de este artículo es conocer el contenido de L-Lisina, L-Arginina y la osmolaridad en las soluciones de aminoácidos autorizadas en España hasta marzo de 2021 y comparar la composición de éstas con las características de las soluciones nefroprotectoras indicadas en la ficha técnica de Lutecio. Métodos: Revisión de las fichas técnicas de todas aquellas soluciones de aminoácidos comercializadas en España. Las presentaciones comerciales con otros macronutrientes o electrolitos que no tengan una función de estabilidad o conservación de la solución fueron excluidas. Resultados: De las 23.658 presentaciones a marzo de 2021, fueron seleccionadas 90 soluciones. Tras esta primera selección, 18 presentaciones comerciales cumplían los criterios de inclusión. De las soluciones incluidas, al extrapolar el contenido a un volumen máximo de 2000 ml, cumplían con los objetivos de L-Lisina y L-Arginina. El contenido difería entre presentaciones pero contenían más L-Arginina y presentaban una alta osmolaridad. Discusión: Empleando un volumen máximo de 2000 ml, la mayoría de las soluciones incluidas en el estudio cumplían con los requisitos de L-Lisina y L-Arginina indicadas en la ficha técnica, si bien pueden existir problemas de administración por vía periférica por su osmolaridad. El hecho de que incluyan otros aminoácidos podría dar lugar a otro tipo de efectos adversos como toxicidad gastrointestinal. (AU)

Introduction: Peptide Receptor Radionuclide Therapy represents an effective therapeutic strategy against neuroendocrine tumors, but it is not without serious adverse effects such as nephrotoxicity. In order to prevent this nephrotoxicity, Lysine and Arginine amino acid solutions are used. The objectives of this article are to to know the content of L-Lysine, L-Arginine and the osmolarity in commercial amino acid solutions authorized in Spain until march 2021 and to compare their composition with the characteristics of the nephroprotective solutions indicated in the Lutetium technical data sheet. Methods: Review of all the technical sheets of all those amino acid solutions that were marketed in Spain. Commercial presentations with other macronutrients or electrolytes that do not have a stability or solution conservation function were excluded. Results: From the 23,658 commercial presentations as of march 2021, 90 parenteral nutrition solutions were selected. After this first selection, 18 commercial presentations met the inclusion criteria. Of the included solutions, when the content was extrapolated to a maximum volume of 2000 ml, they met the objectives of L-Lysine and L-Arginine. The content varied between solutions and was mostly the highest content in L-Arginine. The solutions studied had a high osmolarity. Discussion: Using a maximum volume of 2000 ml, most of the solutions included in the study fulfilled the requirements of the content of L-Lysine and L-Arginine indicated in the technical data sheet, although there may be problems of administration by peripheral route to the have a high osmolarity. The fact that they include other amino acids could lead to other types of adverse effects such as gastrointestinal toxicity. (AU)

Assessing the nitric oxide and asymmetric dimethylarginine levels in lifelong premature ejaculation: A prospective study / Evaluación de los niveles de óxido nítrico y dimetilarginina asimétrica en la eyaculación precoz de por vida, un estudio prospectivo

Objective: To evaluate nitric oxide (NO) and asymmetric dimethylarginine (ADMA) levels in men with premature ejaculation (PE), which is a common condition that adversely affects quality of life. Material and method: Of the 20–50-year old men presenting to the urology clinic, who were married or had regular sexual intercourse, 40 that were diagnosed with lifelong PE according to the Premature Ejaculation Diagnostic Tool (PEDT) and intravaginal ejaculation latency time (IELT) measured by a stopwatch were included in the study. The results of the PE group were compared to those of the control group formed with 40 healthy hospital personnel. Venous blood samples were centrifuged and stored at −80°C. The NO and ADMA values were compared between the individuals with and without PE. Results: There was no statistically significant difference between the groups in terms of age, body mass index (BMI), and The International Erectile Dysfunction Index-5 (IIEF-5) questionnaire scores. The NO and ADMA values were significantly lower in the PE group than in the control group (29.76±13.26μmol/L vs. 48.27±22.71μmol/L; p<0.001 and 1.01±0.49nmol/ml vs. 1.83±1.06nmol/ml; p<0.001, respectively). There was a significant correlation between IELT and NO levels (r=0.407, p=0.001). Conclusion: Our study can contribute to the explanation of the pathophysiology of PE having unclear etiology and treatment. Further studies on these molecules with larger case series are required for the diagnosis and treatment of PE. (AU)

Objetivo: Evaluar los niveles de óxido nítrico (NO) y dimetilarginina asimétrica en hombres con eyaculación precoz (EP), que es una afección común que afecta negativamente la calidad de vida. Material y método: De los hombres de 20 a 50 años que acudieron a la clínica de urología, que estaban casados o tenían relaciones sexuales regulares, se incluyeron en el estudio 40 que fueron diagnosticados con EP de por vida según la Herramienta de Diagnóstico de la Eyaculación Precoz y el tiempo de latencia de la eyaculación intravaginal medidos por un cronómetro. Se compararon los resultados del grupo de EP con los del grupo control formado por 40 personas sanas del hospital. Las muestras de sangre venosa se centrifugaron y almacenaron a −80°C. Se compararon los valores de NO y dimetilarginina asimétrica entre los individuos con y sin EP. Resultados: No hubo diferencias estadísticamente significativas entre los grupos en términos de edad, índice de masa corporal y puntajes del cuestionario International Erectile Dysfunction Index-5. Los valores de NO y dimetilarginina asimétrica fueron significativamente más bajos en el grupo de EP que en el grupo control (29,76±13,26 frente a 48,27±22,71μmol/l [p<0,001] y 1,01±0,49 frente a 1,83±1,06nmol/ml [p<0,001], respectivamente). Hubo una correlación significativa entre los niveles de tiempo de latencia de la eyaculación intravaginal y NO (r=0,407, p=0,001). Conclusión: Nuestro estudio puede contribuir a la explicación de la fisiopatología de la EP de etiología y tratamiento poco claros. Se requieren más estudios sobre estas moléculas con series de casos más grandes para el diagnóstico y tratamiento de la EP. (AU)

Inmunonutrición, cirugía y oncología: un modelo de atenciónnutricional basado en la evidencia / Immunonutrition, surgery and oncology: an evidence-based model of nutritional care

Introducción: La presente revisión de literatura permiteproponer un modelo de acción para identificar oportunamentelos pacientes que requieren cirugía mayor y que puedan be-neficiarse de intervenciones nutricionales como la inmunonu-trición a partir de la evidencia científica. Objetivo: El propósito de esta revisión y síntesis es pro-poner un modelo intervención nutricional en el manejo nutri-cional de los pacientes en el perioperatorio.Material y métodos: Se realizó una revisión rápida de laliteratura, a partir de la consulta en las siguientes fuentes dedatos,EMBASE, MEDLINE (Pubmed), Cochrane Database ofSystematic Reviews (Wiley), LILACS (BVS, interfaz iAHx) y elmotor de búsqueda Google Académico. Resultados: Se identificaron 40 artículos, que cumplieroncon los parámetros establecidos para la revisión sistemática ylos criterios de calidad, que permitieron establecer cuatro fa-ses para la propuesta de intervención nutricional en el manejonutricional perioperatorio, tamización nutricional de rutina enconsulta externa, suplementación preoperatoria con dosis te-rapéutica de inmunonutrición, intervención nutricional intra-hospitalaria y seguimiento nutricional postoperatorio.(AU)

Background: The present literature review allows us topropose a model of action for the timely identification of pa-tients who require major surgery and who may benefit fromnutritional interventions such as immunonutrition based onscientific evidence. Objective: The purpose of this review and synthesis is topropose a nutritional intervention model in the nutritionalmanagement of perioperative patients. Material and methods: A quick review of the literaturewas carried out, based on consultation of the following datasources, EMBASE, MEDLINE (Pubmed), Cochrane Database ofSystematic Reviews (Wiley), LILACS (BVS, iAHx interface) andthe Google Scholar search engine. Results: As a result, 40 articles were identified, which metthe parameters established for the systematic review and the quality criteria, which allowed establishing four phases for theproposal of nutritional intervention 360 in perioperative nutri-tional management, routine nutritional screening in outpa-tient clinic, preoperative supplementation with therapeuticdoses of immunonutrition, in-hospital nutritional interventionand postoperative nutritional follow-up. Conclusion: A nutritional intervention model that includesa nutritional contribution with a formula of amino acids (argi-nine and/or glutamine), polyunsaturated fatty acids (omega-3fatty acid) and a mixture of nucleotides or RNA, is a cost-ef-fective strategy in elective surgery patients for gastrointestinalcancer (stomach and colon cancer), head and neck surgery,patients over 18 years of age.(AU)

A comparison effects of l-citrulline and l-arginine against cyclosporine-induced blood pressure and biochemical changes in the rats / Comparación de los efectos de L-citrulina y L-arginina frente a la presión arterial inducida por ciclosporina y los cambios bioquímicos en ratas

Objective: The use of cyclosporine A (CsA) is associated with different adverse effects including hypertension and nephrotoxicity. The present study aimed to compare the inhibitory effects of l-arginine & l-citrulline on CsA-induced blood pressure and biochemical changes in the serum of rats. Methods: Thirty-six rats were divided into 6 groups received daily: (1) 1ml distilled water, (2) 200mg/kg l-citrulline IP, (3) 25mg/kg CsA SC, (4) CsA+l-citrulline with the same dose of the former groups, (5) 200mg/kg l-arginine IP and (6) l-arginie+CsA with the same doses of group 4 for 7 days. Results: The changes in the blood pressure, heart rate, creatinine, BUN, glucose and C-reactive protein (CRP) of the serum were determined in the treated animals. Significant (p<0.001) increase was shown in the blood pressure and heart rate of CsA treated rats compared to the control group. There were also a significant (p<0.05) increase in the creatinine, BUN and glucose, but a decrease in the CRP value in the CsA-treated group. However, l-citrulline significantly (p<0.001) inhibited the changes in the blood pressure and heart rate in CsA-treated as well as it was able to reduce blood pressure in non-treated group significantly (p<0.01). l-citrulline also inhibited the increased levels of BUN and creatinine induced by CsA, while, l-arginine was able to prevent the increased blood pressure and creatinine occurs after administration of CsA. Conclusions: These findings suggest that the l-citrulline is more efficient than l-arginine against the adverse effects induced by cyclosporine. (AU)

Objetivo: El uso de ciclosporina A (CsA) está asociado a diferentes efectos adversos que incluyen hipertensión y nefrotoxicidad. El objetivo del presente estudio es comparar los efectos inhibitorios de L-arginina y L-citrulina en la presión arterial inducida por CsA, y los cambios bioquímicos a nivel sérico en ratas. Métodos: Se dividieron 36 ratas en 6 grupos, que recibieron diariamente: 1) 1ml de agua destilada, 2) 200mg/kg de L-citrulina IP, 3) 25mg/kg de CsA SC, 4) la misma dosificación que los grupos anteriores de CsA+L-citrulina, 5) 200mg/kg de L-arginina IP y 6) la misma dosificación que el grupo 4 durante 7 días de L-arginina+CsA. Resultados: Se determinaron los cambios de presión arterial, frecuencia cardiaca, creatinina, BUN, glucosa y proteína C reactiva (PCR) a nivel sérico, en los animales tratados. Se observó un incremento significativo (p<0,001) de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA en comparación con el grupo control. También se produjo un incremento significativo (p<0,05) de los niveles de creatinina, BUN y glucosa, y una reducción del valor de PCR en el grupo tratado con CsA. Sin embargo, L-citrulina inhibió significativamente (p<0,001) los cambios de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA, y también pudo reducir la presión arterial de manera considerable en el grupo no tratado (p<0,01). L-citrulina inhibió también los niveles incrementados de BUN y creatinina inducidos por CsA, y L-arginina fue capaz de impedir la incidencia del incremento de presión arterial y creatinina tras la administración de CsA. Conclusiones: Estos hallazgos sugieren que L-citrulina es más efectiva que L-arginina frente a los efectos adversos inducidos por ciclosporina. (AU)

ADMA mediates gastric cancer cell migration and invasion via Wnt/B-catenin signaling pathway

Objective To explore the role of ADMA in gastric cancer. Methods The specimens of 115 gastric cancer patients were analyzed by ELISA and survival analysis. Functional assays were used to assess the effects of ADMA on gastric cancer cells. Experiments were conducted to detect the signaling pathway induced by ADMA in GC. Results Gastric cancer patients with high ADMA levels had poor prognosis and low survival rate. Furthermore, high level of ADMA did not affect the proliferation while promoted the migration and invasion of gastric cancer cell. Moreover, ADMA enhanced the epithelial–mesenchymal transition (EMT). Importantly, ADMA positively regulated β-catenin expression in GC and promoted GC migration and invasion via Wnt/β-catenin pathway. Conclusions ADMA regulates gastric cancer cell migration and invasion via Wnt/β-catenin signaling pathway and which may be applied to clinical practice as a diagnostic and prognostic biomarker (AU)

Analysis of serum levels L-arginine and 25-hydroxyvitamin D as a predictor of survival of severe preeclampsia mothers

Objective: This study aimed to analyze serum levels of L-arginine and 25-hydroxyvitamin D as predictors of survival in severely preeclamptic women. Methods: This study is a retrospective descriptive study using medical record data from June to August 2019 and has received a recommendation for ethical approval with the protocol number UH20070290. The study was conducted in 4 hospitals in Makassar: Dr. General Hospital. Wahidin Sudirohusodo, Hasanuddin University Teaching Hospital, Siti Fatimah Regional Mother and Child Health Hospital, and Sitti Khadijah 1 Mother and Child Hospital. The samples of this study were mothers who gave birth with a diagnosis of normal pregnant women, severe preeclampsia, and severe preeclampsia with complications. Results: Serum l-arginine level did not affect the survival of severe preeclamptic mothers. It was shown at p-value 0.799 > 0.05. Meanwhile, serum levels of 25-hydroxyvitamin D affect the predictors of maternal preeclampsia where the p-value is 0.024 < 0.05. In comparing serum levels of L-arginine and 25-hydroxyvitamin D, there was no significant difference in groups of normal pregnant women, severe preeclampsia, and severe preeclampsia with complications. Conclusion: Serum level of 25-hydroxyvitamin affects the survival of severe preeclamptic mothers. (AU)

Afectación encefálica global y uso de L-arginina en un paciente con síndrome de MELAS / Global cerebral involvement and L-arginine use in a patient with MELAS síndrome

No disponible

Carglumic acid (Carbaglu(R)) treatment in hyperammonemia post liver transplantation / Tratamiento con ácido carglúmico (Carbaglu(R)) en la hiperamoniemia post transplante hepático

No disponible

Postoperative enteral immunonutrition in head and neck cancer patients: Impact on clinical outcomes / Uso de inmunonutrición enteral en el postoperatorio de pacientes con cáncer de cabeza y cuello: impacto en los resultados clínicos

Background: Head and neck cancer patients have a high rate of complications during the postoperative period that could increase their morbidity rate. Arginine has been shown to improve healing and to modulate inflammation and immune response. The aim of our study was to assess whether use of arginine-enriched enteral formulas could decrease fistulas and length of stay (LoS). Methods. A retrospective study was conducted in patients who had undergone head and neck cancer surgery and were receiving enteral nutrition through a nasogastric tube in the postoperative period between January 2012 and May 2018. The differences associated to use of immunoformula vs. standard formulas were analysed. Sociodemographic, anthropometric, and nutritional intervention variables, as well as nutritional parameters, were recorded during the early postoperative period. Occurrence of complications (fistulas), length of hospital stay, readmissions, and 90-day mortality were recorded. Results: In a univariate analysis, patients who received nutritional support with immunonutrition had a lower fistula occurrence rate (17.91% vs. 32.84%; p = 0.047) and a shorter mean LoS [28.25 (SD 16.11) vs. 35.50 (SD 25.73) days; p = 0.030]. After adjusting for age, energy intake, aggressiveness of surgery and tumour stage, fistula occurrence rate and LoS were similar in both groups irrespective of the type of formula. Conclusions: Use of arginine-enriched enteral nutrition appears to decrease the occurrence of fistulas in the postoperative period in patients with head and neck cancer, with a resultant reduction in length of hospital stay. However, the differences disappeared after adjusting for age, tumour stage, or aggressiveness of the surgery

Introducción: El postoperatorio de los pacientes con cáncer de cabeza y cuello presenta una alta tasa de complicaciones. Esta circunstancia podría aumentar la morbilidad en estos pacientes. La arginina ha demostrado mejorar la curación y modular la inflamación y la respuesta inmune. Nuestro planteamiento es valorar si el uso de fórmulas de alimentación enteral enriquecidas con arginina podría reducir la aparición de fístulas y la duración de la estancia hospitalaria. Métodos: Estudio retrospectivo en pacientes intervenidos de cáncer de cabeza y cuello que recibieron nutrición enteral a través de una sonda nasogástrica en el periodo postoperatorio entre enero de 2012 y mayo de 2018. Se analizaron las diferencias asociadas a la utilización de inmunofórmula vs. fórmulas estándar. Se recogieron variables sociodemográficas, antropométricas, de intervención nutricional y de parámetros nutricionales durante el postoperatorio inmediato, así como la aparición de complicaciones (fístulas), la duración de la estancia hospitalaria, los reingresos y la mortalidad a 90 días. Resultados: En el análisis univariante los pacientes que recibieron apoyo nutricional con inmunonutrición presentaron menor tasa de aparición de fístulas (17,91 vs. 32,84%; p = 0,047) y menor estancia hospitalaria (28,25 [DE 16,11] vs. 35,50 [DE 25,73] días; p = 0,030). Después de ajustar por edad, aporte calórico, agresividad de la cirugía y estadio del tumor, la incidencia de fístula y la estancia hospitalaria fueron similares entre los grupos, independientemente del tipo de fórmula. Conclusiones: El uso de nutrición enteral enriquecida con arginina en pacientes con cáncer de cabeza y cuello intervenidos podría reducir el desarrollo de la fístula y la duración de la estancia hospitalaria; sin embargo, las diferencias observadas desaparecen después de ajustar por edad, estadio tumoral o agresividad de la cirugía

Efecto de la suplementación de L-arginina y L-citrulina sobre el rendimiento físico: una revisión sistemática / The effect of supplementation with L-arginine and L-citrulline on physical performance: a systematic review

Introducción: los aminoácidos L-arginina (L-arg) y L-citrulina (L-citr) se han utilizado dentro de la nutrición deportiva y se cree que ejercen un efecto sobre el rendimiento físico. Sin embargo, la información existente es variada y poco concluyente. Objetivo: revisar y analizar la evidencia científica existente dentro de los últimos diez años que relacionó los efectos de la suplementación con L-arg y L-citr sobre el rendimiento físico. Material y método: el estudio corresponde a una revisión sistemática de estudios previamente publicados, siguiendo el modelo PRISMA. Se evaluaron artículos publicados entre los años 2008 y 2018 que relacionaron la suplementación de L-arg y L-citr sobre el rendimiento físico. La búsqueda electrónica se realizó a través de Web of Science, Scopus, Sport Discus, PubMed, Medline. Se incluyeron todos los artículos que utilizaron un protocolo de suplementación de estos aminoácidos por separado o en conjunto. Resultados: se encontraron 38 artículos, los que se estratificaron según el protocolo utilizado: a) suplementación con L-arg (n = 19); b) suplementación con L-arg y L-citr (n = 1); y c) suplementación con L-citr (n = 18), tanto de corta duración como prolongada. Conclusión: existe evidencia de que la L-citr puede funcionar mejor como ayuda ergogénica que la L-arg sobre el rendimiento físico, ya que la L-citr mostró un efecto positivo sobre la percepción subjetiva del esfuerzo y el dolor muscular, además de una disminución en las concentraciones de lactato y una disminución del tiempo en pruebas máximas. Sin embargo, aún falta evidencia para establecer la dosis de L-citr beneficiosa para el rendimiento físico

Introduction: the amino acids L-arginine (L-arg) and L-citrulline (L-citr) have been used in sports nutrition, and it is believed that they have an effect on physical performance. However, current information is varied and inconclusive. Objective: to review and analyze the scientific evidence in the last ten years, which reflects a connection between the effect of L-arg and L-citr supplementation and physical performance. Material and method: this study is a systematic review of articles previously published, following the PRISMA model. Those articles published between 2008 and 2018 that connected the effect of L-arg and L-citr supplementation with physical performance were analyzed. The electronic search was performed on Web of Science, Scopus, Sport Discus, PubMed, and Medline. All articles using a supplementation protocol with these amino acids, separately or in groups, were selected. Results: a total of 38 articles were found, which were stratified according to the established protocol: a) supplementation with L-arg (n = 19); b) supplementation with L-arg and L-citr (n = 1); and c) supplementation with L-citr (n = 18), whether of short or prolonged duration. Conclusion: there is evidence that L-citr works better as ergogenic than L-arg does on physical performance, since L-citr showed a positive effect on the rate of perceived exertion and muscular pain, in addition to a decrease in lactate concentrations and time in maximum tests. However, there is not enough evidence to establish a beneficial L-citr dosage for physical performance

Evaluación positiva de medicamentos: marzo, abril y mayo 2019 / Possitive assesment of drugs: March, April and May 2019

Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento publicados en marzo y abril de 2018, considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product

Effect of l-arginine intake on exercise-induced hypotension / Efecto de la ingestión de L-arginina en la hipotensión inducida por el ejercicio

Objective: to verify if one single dose of L-arginine improves post-exercise hypotension (PEH) in hypertensive. Methods: double-blind, placebo, randomized with 20 hypertensive (51.47 ± 1.24 years). Two sessions of aerobic exercise were performed proceeded for the ingestion of one dose of 7 g of L-arginine (EX-LARG) or placebo (EX-PLA), plus one session only with L-arginine ingestion (L-ARG). Blood pressure (BP) was measured at rest, and each ten minutes for a period of 60 minutes recovery after exercise. Blood samples were taken before and after exercise for analysis of plasma concentration of nitrite and malondial de hyde (MDA). One-way ANOVA tests were used to compare the baseline conditions and two-way ANOVA, to evaluate possible differences in pressure responses between procedures. Results: both sessions EX-LARG and EX-PLA showed similar peak reduction for the mean systolic blood pressure (-6.58 ± 0.95 mmHg and -8.38 ± 1.29 mmHg respectively, p = 0.28). On the other hand, for the diastolic component, only L-ARG was able to promote PEH (-1.85 ± 0.44 mmHg), significantly better than EX-PLA (+2.13 ± 0.62 mmHg; p < 0.01). L-ARG alone did not result in significant changes in BP. Nitrite and MDA behaved similarly between procedures. Conclusion: a single dose of L-arginine before exercise improves diastolic PEH

Objetivo: verificar si una sola dosis de L-arginina mejora la hipotensión post-ejercicio (HPE) en hipertensos. Métodos: estudio doble ciego, placebo, aleatorizado con 20 hipertensos (51,47 ± 1,24 anos). Se realizaron dos sesiones de ejercicio aeróbico para la ingestión de una dosis de 7 g de L-arginina (EX-LARG) o placebo (EX-PLA), mas una sesión solo con ingestión de L-arginina (L-ARG). La presión arterial (PA) se midió en reposo y cada diez minutos durante un periodo de recuperación de 60 minutos después del ejercicio. Se tomaron muestras de sangre antes y después del ejercicio para el análisis de la concentración plasmática de nitrito y malondialdehido (MDA). Se usaron pruebas de ANOVA de una via para comparar las condiciones iniciales y ANOVA de dos vías para evaluar las posibles diferencias en las respuestas de presión entre procedimientos. Resultados: ambas sesiones, EX-LARG y EX-PLA, mostraron una reducción máxima similar de la presión arterial sistólica media (-6,58 ± 0,95 mmHg y -8,38 ± 1,29 mmHg, respectivamente, p = 0,28). Por otro lado, con respecto al componente diastólico, solo L-ARG fue capaz de promover HPE (-1,85 ± 0,44 mmHg), significativamente mejor que EX-PLA (+2,13 ± 0,62 mmHg, p < 0,01). L-ARG solo no dio como resultado un cambio significativo en la PA. El nitrito y la MDA se comportaron de manera similar entre los procedimientos. Conclusión: una dosis unica de L-arginina antes del ejercicio mejora la HPE diastolic

Early obesity leads to increases in hepatic arginase I and related systemic changes in nitric oxide and l-arginine metabolism in mice

Obesity is a risk factor for vascular endothelial cell dysfunction characterized by low-grade, chronic inflammation. Increased levels of arginase I and concomitant decreases in l-arginine bioavailability are known to play a role in the pathogenesis of vascular endothelial cell dysfunction. In the present study, we focused on changes in the systemic expression of arginase I as well as l-arginine metabolism in the pre-disease state of early obesity prior to the onset of atherosclerosis. C57BL/6 mice were fed a control diet (CD; 10% fat) or high-fat diet (HFD; 60% fat) for 8 weeks. The mRNA expression of arginase I in the liver, adipose tissue, aorta, and muscle; protein expression of arginase I in the liver and plasma; and systemic levels of l-arginine bioavailability and NO2 − were assessed. HFD-fed mice showed early obesity without severe disease symptoms. Arginase I mRNA and protein expression levels in the liver were significantly higher in HFD-fed obese mice than in CD-fed mice. Arginase I levels were slightly increased, whereas l-arginine levels were significantly reduced, and these changes were followed by reductions in NO2 − levels. Furthermore, hepatic arginase I levels positively correlated with plasma arginase I levels and negatively correlated with l-arginine bioavailability in plasma. These results suggested that increases in the expression of hepatic arginase I and reductions in plasma l-arginine and NO2 − levels might lead to vascular endothelial dysfunction in the pre-disease state of early obesity

Efeitos da ingestão de semente de linhaça e seu possivel efeito hipocolesterolêmico / Effects of linseed intake and its possible hypocholesterolemic effects

Introdução: O colesterol é essencial para a vida. Em excesso no sangue, deposita-se nas paredes das artérias promovendo seu estreitamento ou obstrução. Objetivos: O objetivo foi verificar o possível efeito hipocolesterolêmico da semente de linhaça. Materiais e Métodos: Utilizaram-se 30 ratos Wistar fêmeas divididos em três grupos: Controle, Hipercolesterolêmico, e Linhaça. Os parâmetros avaliados foram: ingestão hídrica; ingestão de ração; peso corporal; gordura peritoneal e níveis de colesterol; Resultados e Discussão: O grupo controle apresentou maior ingestão hídrica (57,46 ± 0,13mL) e ração (30,68 ± 1,96g) quando comparados ao hipercolesterolêmico e linhaça; Para peso corporal total, somente o controle não sofreu alteração; Em relação ao acúmulo de gordura peritoneal, o grupo hipercolesterolêmico se sobressaiu (17,06 ± 3,99g) em comparação ao linhaça e ao controle; para os níveis de colesterol sérico, o grupo controle obteve (1,14 ± 0,14g), sendo observado portanto no grupo linhaça (1,66 ± 0,16g), uma maior aproximação para o resultado do grupo controle do que do hipercolesterolêmico (2,20 ± 6,32g), resultado que nos leva a reconhecer que a linhaça surtiu efeito benéfico sobre o colesterol. Conclusão: Os resultados obtidos demonstram benefícios na utilização da semente para redução dos níveis de gordura peritoneal, peso total e colesterol

Introduction: Cholesterol is essential for life, when in excess in blood, is deposited on the artery walls promoting its narrowing or obstruction. Objectives: The objective was to verify the possible hypocholesterolemic effect of linseed. Methods: We used 30 female Wistar rats divided into three groups: control, hypercholesterolemic, and linseed. The evaluated parameters were: water intake, feed intake, body weight, peritoneal fat, and cholesterol levels; Results and Discussion: The results were: the control group had a higher fluid intake (57.46 ± 0.13ml) and feed (30.68 ± 1.96g) when compared to hypercholesterolemic and linseed; for total body weight, only the control group did not change; in relation to the accumulation of peritoneal fat, the hypercholesterolemic group stood out (17.06 ± 3.99g) compared to linseed and control; for serum cholesterol levels, the control group obtained (1.14 ± 0.14g), thus being observed in linseed group (1.66 ± 0.16g), closer to the result of the control group than the hypercholesterolemic (2.20 ± 6.32g), a result that leads us to recognize that linseed has had a beneficial effect on cholesterol.Conclusion: The results obtained demonstrate benefits in the use of the seed to reduce levels of peritoneal fat, total weight and cholesterol

No disponible

Divergent functional roles of D-amino acids secreted by Vibrio cholera

The L-forms of amino acids are used in all kingdoms of life to synthesize proteins. However, the bacterium Vibrio cholerae, the causative agent of cholera, produces D-amino acids which are released to the environment at millimolar concentrations. We baptized these D-amino acids as non-canonical D-amino acids (NCDAAs) since they are different from those (i.e. D-alanine and D-glutamate) normally present in the bacterial cell wall. In V. cholerae, production of NCDAAs relies on the BsrV enzyme, a periplasmic broad spectrum racemase. BsrV multispecific activity, produces of a wide range of distinct D-amino acids. Using a combination of genetics and molecular physiology approaches we have demonstrated that NCDAAs target different cellular processes which may function as part of a cooperative strategy in vibrio communities to protect non-producing members from competing bacteria. Because NCDAA production is widespread in bacteria, we anticipate that NCDAAs are relevant modulators of microbial subpopulations in diverse ecosystems (AU)

No disponible

The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus

In diabetes mellitus, chronic hyperglycemia leads to formation of advanced glycation end products (AGEs). Binding of AGEs to receptors of AGE (RAGE) causes deleterious effects. In populations with a high consumption of n-3 long-chain polyunsaturated fatty acids, a lower prevalence of diabetes mellitus has been reported. We aimed to investigate the effects of n-3 fatty acid (EPA and DHA) supplementation on the levels of AGEs (carboxymethyl lysine (CML) and pentosidine), sRAGE, and nuclear factor kappa B (NF-kB) in type 2 diabetes mellitus (T2DM). T2DM patients (n = 38) treated with oral hypoglycemic agents, without insulin were supplemented with n-3 fatty acids (1.2 g/day) for 2 months. Plasma CML, pentosidine, sRAGE, and NF-kB levels were measured by ELISA both before and after the supplementation. n-3 fatty acid supplementation significantly reduced fasting glucose (p < 0.01), glycated hemoglobin (HbA1c) (p < 0.05), and pentosidine (p < 0.05) levels. The supplementation induced percentage changes in pentosidine and HbA1c and in pentosidine and creatinine were observed to be correlated (r = 0.349, p < 0.05) and (r = 0.377, p < 0.05), respectively. Waist circumference and systolic and diastolic pressures were significantly decreased due to n-3 supplementation (p < 0.001, p < 0.01, p < 0.01), respectively. Our results show that supplementation with n-3 fatty acid has beneficial effects on waist circumference; systolic and diastolic blood pressures; and the levels of glucose, HbA1c, and pentosidine in T2DM patients. However, the supplementation failed to decrease these parameters to the reference ranges for healthy subjects. In addition, the supplementation did not appear to induce any significant differences in CML, sRAGE, or NF-kB (AU)

No disponible

Aerobic training and l-arginine supplementation promotes rat heart and hindleg muscles arteriogenesis after myocardial infarction

Arteriogenesis is a main defense mechanism to prevent heart and local tissues dysfunction in occlusive artery disease. TGF-β and angiostatin have a pivotal role in arteriogenesis. We tested the hypothesis that aerobic training and l-arginine supplementation promotes cardiac and skeletal muscles arteriogenesis after myocardial infarction (MI) parallel to upregulation of TGF-β and downregulation of angiostatin. For this purpose, 4 weeks after LAD occlusion, 50 male Wistar rats were randomly distributed into five groups: (1) sham surgery without MI (sham, n = 10), (2) control-MI (Con-MI, n = 10), (3) l-arginine-MI (La-MI, n = 10), (4) exercise training-MI (Ex-MI, n = 10), and (5) exercise and l-arginine-MI (Ex + La-MI). Exercise training groups running on a treadmill for 10 weeks with moderate intensity. Rats in the l-arginine-treated groups drank water containing 4 % l-arginine. Arteriolar density with different diameters (11-25, 26-50, 51-75, and 76-150 μm), TGF-β, and angiostatin gene expression were measured in cardiac (area at risk) and skeletal (soleus and gastrocnemius) muscles. Smaller arterioles decreased in cardiac after MI. Aerobic training and l-arginine increased the number of cardiac arterioles with 11-25 and 26-50 μm diameters parallel to TGF-β overexpression. In gastrocnemius muscle, the number of arterioles/mm2 was only increased in the 11 to 25 μm in response to training with and without l-arginine parallel to angiostatin downregulation. Soleus arteriolar density with different size was not different between experimental groups. Results showed that 10 weeks aerobic exercise training and l-arginine supplementation promotes arteriogenesis of heart and gastrocnemius muscles parallel to overexpression of TGF-β and downregulation of angiostatin in MI rats (AU)

No disponible

La cinética de la citrulina y la arginina y su valor como factor pronóstico en pacientes pediátricos críticamente enfermos / The value of the kinetics of citrulline and arginine as a prognostic factor in critically ill paediatric patients

No disponible

La cinética de la citrulina y la arginina y su valor como factor pronóstico en pacientes pediátricos críticamente enfermos. Respuesta de los autores / The value of the kinetics of citrulline andarginine as a prognostic factor in critically ill paediatric patients. Author's reply

No disponible